Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zevalin On Track For Medicare ASP-Based Reimbursement In 2010

This article was originally published in The Pink Sheet Daily

Executive Summary

Change to average sales price based payment for Cell Therapeutics’ radioimmunotherapy could help boost use in community oncology centers.

You may also be interested in...

Broader Zevalin NHL Label: 18 Times More Use?

New indication sought in sBLA could mean whopper sales, CTI exec says.

ASP-based Reimbursement For Radiopharmaceuticals Gets PhRMA Support

The Pharmaceutical Research and Manufacturers of America expressed support for using an average sales price-based approach to reimbursing radiopharmaceuticals under Medicare in response to CMS' statement of its willingness to consider switching from reimbursement based on individual hospitals' claims

Radiopharmaceuticals May Be Eligible For ASP Reimbursement Under CMS Proposal

Two key drugs likely to be affected by such a change are Cell Therapeutics’ Zevalin and GlaxoSmithKline’s Bexxar.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts